Athersys (ATHX) Competitors

Athersys (NASDAQ:ATHX) and Purple Biotech (NASDAQ:PPBT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, community ranking, dividends, profitability, earnings, analyst recommendations, risk, institutional ownership and media sentiment.

Does the media favor ATHX or PPBT?

In the previous week, Athersys and Athersys both had 1 articles in the media. Athersys' average media sentiment score of 0.00 equaled Purple Biotech'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Athersys	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Purple Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has preferable earnings and valuation, ATHX or PPBT?

Purple Biotech has lower revenue, but higher earnings than Athersys. Purple Biotech is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athersys	$146K	0.00	-$72.53M	-$2.03	N/A
Purple Biotech	N/A	N/A	-$19.88M	-$5.25	-0.54

Do insiders & institutionals have more ownership in ATHX or PPBT?

19.4% of Athersys shares are held by institutional investors. Comparatively, 9.6% of Purple Biotech shares are held by institutional investors. 0.0% of Athersys shares are held by insiders. Comparatively, 3.0% of Purple Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Is ATHX or PPBT more profitable?

Athersys' return on equity of 0.00% beat Purple Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athersys	N/A	N/A	-223.03%
Purple Biotech	N/A	-55.86%	-44.67%

Which has more risk and volatility, ATHX or PPBT?

Athersys has a beta of -0.9, indicating that its share price is 190% less volatile than the S&P 500. Comparatively, Purple Biotech has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500.

Do analysts rate ATHX or PPBT?

Purple Biotech has a consensus target price of $33.00, indicating a potential upside of 1,061.97%. Given Purple Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Purple Biotech is more favorable than Athersys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athersys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Purple Biotech	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the MarketBeat Community favor ATHX or PPBT?

Athersys received 348 more outperform votes than Purple Biotech when rated by MarketBeat users. However, 94.44% of users gave Purple Biotech an outperform vote while only 56.50% of users gave Athersys an outperform vote.

Company	Underperform	Outperform
Athersys	Outperform Votes 365 56.50%	Underperform Votes 281 43.50%
Purple Biotech	Outperform Votes 17 94.44%	Underperform Votes 1 5.56%

Summary

Purple Biotech beats Athersys on 8 of the 14 factors compared between the two stocks.